<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MoleMax Systems</title>
	<atom:link href="https://molemaxsystems.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://molemaxsystems.com/</link>
	<description>Provide the best skin imaging device</description>
	<lastBuildDate>Tue, 23 Jun 2026 07:35:45 +0000</lastBuildDate>
	<language>en-AU</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://molemaxsystems.com/wp-content/uploads/2020/10/favicon.png</url>
	<title>MoleMax Systems</title>
	<link>https://molemaxsystems.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>7-Point Checklist for Melanoma: A Complete Dermoscopy Guide </title>
		<link>https://molemaxsystems.com/7-point-checklist-for-melanoma-a-complete-dermoscopy/</link>
		
		<dc:creator><![CDATA[keshab]]></dc:creator>
		<pubDate>Tue, 23 Jun 2026 07:23:36 +0000</pubDate>
				<category><![CDATA[Mole Mapping & Lesion Tracking]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=10070</guid>

					<description><![CDATA[<p>Melanoma is the deadliest form of skin cancer, but when caught early it is also one of the most treatable. The challenge for clinicians, especially&#160;those outside specialist dermatology, is reliably...</p>
<p>The post <a href="https://molemaxsystems.com/7-point-checklist-for-melanoma-a-complete-dermoscopy/">7-Point Checklist for Melanoma: A Complete Dermoscopy Guide </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Melanoma is the deadliest form of skin cancer, but when caught early it is also one of the most treatable. The challenge for clinicians, especially&nbsp;those outside specialist dermatology, is reliably spotting melanoma among the many benign moles seen every&nbsp;day,&nbsp;&nbsp;turning&nbsp;subjective pattern recognition into a simple scoring system. This guide explains what the checklist is, how it works, and how to apply it in clinical practice.&nbsp;</p>



<h2 class="wp-block-heading">What Is the 7-Point Checklist? </h2>



<p class="wp-block-paragraph">The 7-point checklist is a&nbsp;<strong>7-point&nbsp;checklist&nbsp;dermoscopy</strong>&nbsp;scoring algorithm used to evaluate pigmented skin lesions for features associated with melanoma. It was developed and published in 1998 by Giuseppe Argenziano and his colleagues at the Federico II University of Naples, Italy.&nbsp;</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">The <strong>Argenziano 7-point checklist</strong> was created with a clear goal: to simplify melanoma diagnosis. Earlier methods required clinicians to recognise dozens of subtle dermoscopic patterns.</p>



<p class="wp-block-paragraph"> By reducing the assessment to just seven well-defined features, the checklist made dermoscopy accessible to General Practitioners and trainees, not only specialist dermatologists. </p>



<p class="wp-block-paragraph">In Argenziano&#8217;s original validation study of 342 lesions, the checklist achieved a sensitivity of 95% and a specificity of 75% for melanoma detection. </p>



<h2 class="wp-block-heading">The 7 Dermoscopic Criteria </h2>



<p class="wp-block-paragraph">The seven features fall into two groups based on how strongly each predicts melanoma. Together they capture the most reliable <strong>dermoscopic features of melanoma</strong> and form the basis of the <strong>major and minor criteria of the melanoma</strong> scoring system. </p>



<figure class="wp-block-image size-full is-resized"><img fetchpriority="high" decoding="async" width="509" height="572" src="https://molemaxsystems.com/wp-content/uploads/2023/10/Is-photographic-surveillance-in-melanoma-diagnosis-dispensable.jpg" alt="" class="wp-image-6371" style="aspect-ratio:0.8898678414096917;width:573px;height:auto" srcset="https://molemaxsystems.com/wp-content/uploads/2023/10/Is-photographic-surveillance-in-melanoma-diagnosis-dispensable.jpg 509w, https://molemaxsystems.com/wp-content/uploads/2023/10/Is-photographic-surveillance-in-melanoma-diagnosis-dispensable-267x300.jpg 267w, https://molemaxsystems.com/wp-content/uploads/2023/10/Is-photographic-surveillance-in-melanoma-diagnosis-dispensable-400x450.jpg 400w" sizes="(max-width: 509px) 100vw, 509px" /></figure>



<h3 class="wp-block-heading"><strong>Major Criteria </strong> </h3>



<ol start="1" class="wp-block-list">
<li><strong>Atypical pigment network</strong>: Irregular meshes with thickened lines, abrupt cut-offs, or uneven distribution. </li>
</ol>



<ol start="2" class="wp-block-list">
<li><strong>Blue-white veil</strong>: Irregular, confluent blue-white pigmentation overlying part of the lesion. </li>
</ol>



<ol start="3" class="wp-block-list">
<li><strong>Atypical vascular pattern</strong>: linear-irregular, dotted, or polymorphous blood vessels not seen in benign nevi. </li>
</ol>



<h3 class="wp-block-heading"><strong>Minor Criteria </strong> </h3>



<ol start="4" class="wp-block-list">
<li><strong>Irregular streaks</strong>: Radial pigmented projections at the periphery of the lesion. </li>
</ol>



<ol start="5" class="wp-block-list">
<li><strong>Irregular pigmentation</strong>: Areas of black, brown, or grey distributed asymmetrically. </li>
</ol>



<ol start="6" class="wp-block-list">
<li><strong>Irregular dots and globules</strong>: Varying in size, shape and distribution. </li>
</ol>



<ol start="7" class="wp-block-list">
<li><strong>Regression structures</strong>: White scar-like areas or grey &#8220;peppering,&#8221; suggesting partial immune destruction of the lesion. </li>
</ol>



<h2 class="wp-block-heading">How to Score and Interpret the Result </h2>



<p class="wp-block-paragraph">Calculating a&nbsp;<strong>7-point&nbsp;checklist score</strong>&nbsp;is straightforward: add 2 points for each major criterion present and 1 point for each minor criterion. A total score of&nbsp;<strong>3 or more</strong>&nbsp;should prompt biopsy or excision for histological evaluation.&nbsp;</p>



<p class="wp-block-paragraph">This means melanoma can be flagged in several ways: one major plus one minor (2 + 1 = 3), three minor criteria (1 + 1 + 1 = 3), or any larger combination.</p>



<p class="wp-block-paragraph"> A lesion with no positive criteria scores 0 and is most likely benign, while a lesion with multiple major features can easily reach 5 or 6 and demands urgent attention. </p>



<h3 class="wp-block-heading"><strong>Original vs. Revised 7-Point Checklist</strong>&nbsp;</h3>



<p class="wp-block-paragraph">In 2011, Argenziano and colleagues published the&nbsp;<strong>revised&nbsp;7-point&nbsp;checklist</strong>&nbsp;to address limitations of the original in real-world clinical settings. The revised version assigns just 1 point to every criterion — no separate weighting for major and minor features — while keeping the same threshold of ≥ 3 for excision.&nbsp;</p>



<p class="wp-block-paragraph">The simplified version reports sensitivity of 85–93% with slightly lower specificity (45–48%). It is easier for non-experts to remember and tends to err on the side of caution,&nbsp;referring&nbsp;more lesions for biopsy but missing fewer melanomas. Many primary-care guidelines now recommend the revised version for this reason.&nbsp;</p>



<h3 class="wp-block-heading"><strong>Clinical Application and Limitations</strong>&nbsp;</h3>



<p class="wp-block-paragraph">The checklist works well for the majority of pigmented melanocytic lesions on the trunk and limbs.&nbsp;It is less reliable for:&nbsp;</p>



<ul class="wp-block-list">
<li>Featureless or amelanotic melanomas, which can score 0–2 despite being malignant </li>
</ul>



<ul class="wp-block-list">
<li>Facial lesions, where dermoscopic patterns differ </li>
</ul>



<ul class="wp-block-list">
<li>Acral lesions on palms, soles and nails </li>
</ul>



<ul class="wp-block-list">
<li>Mucosal melanomas </li>
</ul>



<p class="wp-block-paragraph">For these challenging cases, a low score should never be taken as&nbsp;reassurance&nbsp;on its own. Recent research on&nbsp;<a href="https://molemaxsystems.com/identification-of-novel-dermoscopic-patterns-for-featureless-melanoma-clinical-pathological-correlation/" target="_blank" rel="noreferrer noopener">featureless melanoma</a>&nbsp;has&nbsp;identified&nbsp;additional&nbsp;dermoscopic&nbsp;patterns that can flag lesions the original checklist would miss.&nbsp;</p>



<p class="wp-block-paragraph">Accurate scoring also depends heavily on the quality of the&nbsp;dermatoscope&nbsp;used.&nbsp;Polarised&nbsp;light reveals vascular structures and the blue-white veil more clearly than non-polarised&nbsp;light, and good&nbsp;colour&nbsp;rendering is essential for distinguishing regression from benign hypopigmentation. A practical primer on&nbsp;<a href="https://molemaxsystems.com/use-of-the-dermatoscope/" target="_blank" rel="noreferrer noopener">using a dermatoscope</a>&nbsp;is a useful starting point for clinicians new to&nbsp;dermoscopy.&nbsp;</p>



<h3 class="wp-block-heading"><strong>Why Early Detection Matters</strong>&nbsp;</h3>



<p class="wp-block-paragraph">Melanoma incidence is rising worldwide, with Australia and New Zealand bearing the highest burden. Recent projections of&nbsp;<a href="https://molemaxsystems.com/melanoma-burden-rising-new-prevention-campaign-vital/" target="_blank" rel="noreferrer noopener">global melanoma trends</a>&nbsp;suggest more than half a million new cases per year by 2040 if current patterns continue. In this context, even modest improvements in primary-care diagnostic accuracy translate into many lives saved.&nbsp;</p>



<p class="wp-block-paragraph">Tools like the 7-point checklist, combined with digital&nbsp;dermoscopy&nbsp;and total-body photography, give clinicians a structured, defensible approach to skin checks. Imaging systems that support storage, comparison and follow-up — such as those used for&nbsp;<a href="https://molemaxsystems.com/how-molemax-can-be-used-to-detect-skin-cancer/" target="_blank" rel="noreferrer noopener">detecting skin cancer</a>&nbsp;with&nbsp;MoleMax&nbsp;— extend the value of the checklist beyond a single appointment, allowing borderline lesions to be&nbsp;monitored&nbsp;over time rather than excised unnecessarily.&nbsp;</p>



<h3 class="wp-block-heading"><strong>Conclusion</strong>&nbsp;</h3>



<p class="wp-block-paragraph">The 7-point checklist remains one of the most useful and accessible algorithms in dermoscopy. Its strength lies in its simplicity: seven well-defined criteria, a clear scoring system, and a low threshold for action.</p>



<p class="wp-block-paragraph"> For skin cancer clinicians at the front line of detection, mastering the checklist is one of the highest-yield investments of training time available. </p>



<p class="wp-block-paragraph">That said, no algorithm is a substitute for clinical judgement, good&nbsp;equipment&nbsp;and the willingness to biopsy when something simply does not look right. Used alongside high-quality&nbsp;dermatoscopes&nbsp;and digital follow-up, the 7-point checklist helps turn a suspicious mole into a defensible decision — and an early-stage melanoma into a curable one.&nbsp;</p>
<p>The post <a href="https://molemaxsystems.com/7-point-checklist-for-melanoma-a-complete-dermoscopy/">7-Point Checklist for Melanoma: A Complete Dermoscopy Guide </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</title>
		<link>https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 23 Jun 2026 05:03:13 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=10065</guid>

					<description><![CDATA[<p>The post <a href="https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/">Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a3b1584e5be5"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row top-level"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<nav role="none"><span class="wi-fullname brand-fg">Julien Anriot, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Siyuan Yan, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Clio Coste, MD, PhD; </span><span class="wi-fullname brand-fg">Philipp Tschandl, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Loic Verlingue, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Camille Andremasse, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Mona Amini-Adle, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Jean Luc Perrot, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Zongyuan Ge, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Harald Kittler, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Luc Thomas, MD, PhD</span></nav>
<h3><span class="heading-text thm-col h3 cb section-type-keyPoints decorated-hed sb-sc "><br />
<strong>Key Points</strong></span></h3>
<p><strong>Question</strong>  How does artificial intelligence (AI) diagnostic performance compare to human dermatologists of varying experience for skin cancer detection in realistic clinical settings?</p>
<p><strong>Findings</strong>  In this diagnostic study of 652 physicians and 3 AI models evaluating 1117 cases, expert dermatologists (&gt;10 years of experience) achieved the highest accuracy (74.2%), considerably outperforming a modern unimodal foundation model (72.2%), which exceeded dermatologists with less than 1 year of experience (59.1%), while the first-generation convolutional neural network underperformed all readers (56.7%).</p>
<p><strong>Meaning</strong>  Future practice should integrate human-AI collaboration, with AI supporting less experienced clinicians and providing expert triage assistance and help to minimize fatigue-related diagnostic errors.</p>
<p>To read further on this article please <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2849416?guestAccessKey=0150ca00-9e91-4991-91bc-c92587ac78fb&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-recommended-tfl_&amp;utm_term=061726" target="_blank" rel="noopener">click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<p>The post <a href="https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/">Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</title>
		<link>https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 00:33:36 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9963</guid>

					<description><![CDATA[<p>The post <a href="https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/">Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a3b1584e7c9f"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<nav role="none"><span class="wi-fullname brand-fg">Youyou Zhou, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Weiming Zhong, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Xulei Liu, MBBS; </span>Jianglin Zhang, MD, PhD</nav>
<p>&nbsp;</p>
<p>Malignant skin cancers impose an escalating and heterogeneous health burden worldwide.<sup>1</sup> Using the Global Burden of Disease (GBD) 2023 database,<sup>2</sup> we summarize these cancers’ epidemiology, subgroup patterns, and projections to 2050.</p>
<div class="h3 cb section-type-section ">
<h3 class="heading-text thm-col sb-sc"><strong>Methods</strong></h3>
</div>
<p class="para">We analyzed GBD 2023 estimates (1990-2023) for malignant melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma. Outcomes included prevalence and disability-adjusted life-years (DALYs; years of life lost due to premature death plus years lived with disability). Subgroup analyses were conducted by sex, age group, and Sociodemographic Index (SDI; range, 0-1), defined as the geometric mean of indices of fertility in those younger than 25 years, education among those aged 15 years and older, and lag-distributed income per capita. Projections to 2050 used a bayesian age-period-cohort (BAPC) model, a bayesian hierarchical framework that jointly estimates age, period, and cohort effects and provides uncertainty intervals. For basal cell carcinoma, we excluded the 2005 to 2009 surveillance-artifact period and fit projections using 2010 to 2023 data. Additional methods are provided in the eMethods in Supplement 1. This study was deemed to be not human participant research by Shenzhen People’s Hospital; therefore, institutional review board approval and informed consent were not required.</p>
<p>To read this article in full <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2848888?guestAccessKey=2634ca35-bbf2-434d-972c-06ce8df175f5&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-tfl_&amp;utm_term=051326" target="_blank" rel="noopener">please click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<p>The post <a href="https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/">Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</title>
		<link>https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 26 May 2026 02:46:59 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9900</guid>

					<description><![CDATA[<p>The post <a href="https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/">Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a3b1584e9750"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="wi-fullname brand-fg">Yin Li, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Robert A. Swerlick, MD</span></p>
<div class="h3 cb section-type-abstract decorated-hed ">
<h3 class="heading-text thm-col sb-sc"><strong>Abstract</strong></h3>
</div>
<div id="AbstractSection">
<p><strong>Importance</strong>  Periodic comprehensive skin examinations of asymptomatic individuals are widely accepted by dermatologists and the public, resulting in deployment of skin cancer (SC) surveillance practices that may include patients at low risk for SC.</p>
<p><strong>Objective</strong>  To define the demographics, SC risk factors, and near-term outcomes of asymptomatic individuals seeking comprehensive skin examinations.</p>
<p><strong>Design, Setting, and Participants</strong>  This cross-sectional study is a secondary analysis of data collected through a routine, previsit survey completed by patients who visited the Emory Healthcare Dermatology Clinic between March 2021 and October 2022. This study involved new patients who had no specific skin complaints and requested a general skin examination because they had general concerns about SC. Data were analyzed between from July to December 2025.</p>
<p><strong>Main Outcomes and Measures</strong>  The main objective was to identify patients at higher risk for SC development by evaluating characteristics including demographics and SC risk factors including skin phototype, eye and hair color, and family and personal history of SC. The number needed to examine to diagnose 1 SC was calculated for the entire cohort and for subgroups.</p>
<p><strong>Results</strong>  A total of 1074 new patients who noted no skin complaints but sought examinations for concerns about SC were identified (mean [SD] age, 50.3 [15.9] years; 643 [59.9%] female). Of these patients, 186 reported a personal history of SC, with the percentage reporting a history of SC increasing with age. Among those reporting SC history, 184 (99.5%) had skin phototypes I through III. Overall, 131 patients (12.2%) underwent 146 skin biopsies, and 38 SCs were diagnosed. Three patients younger than 50 years were diagnosed with SC, and 37 of 38 SCs were diagnosed in patients with skin types I through III. The number needed to be examined to diagnose 1 SC was 181 in patients 50 years or younger and 7 in patients 70 years or older. The number needed to examine for patients with and without a history of SC was 12 and 52, respectively.</p>
<p><strong>Conclusions and Relevance</strong>  This study found that populations of new patients without specific skin complaints seeking care for SC surveillance may contain substantial percentages of people at low risk for diagnosis of SC. Implementation of simple triage criteria for asymptomatic patients seeking SC surveillance based on age, skin phototype, and SC history could select for patients at substantially higher risk for SC diagnosis.</p>
<p>To read the full article please <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2848896?guestAccessKey=e667353f-cfd2-411f-b6a8-9108619aa0e4&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-tfl_&amp;utm_term=052026" target="_blank" rel="noopener">click here</a>.</p>
</div>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<p>The post <a href="https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/">Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</title>
		<link>https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 12 May 2026 00:26:00 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermoscopy]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9679</guid>

					<description><![CDATA[<p>The post <a href="https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/">Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a3b1584eb256"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Giuseppe Argenziano, Giulia Briatico, Eugenia Veronica Di Brizzi, Camila Scharf, Gabriella Brancaccio, Elvira Moscarella, Maria Maddalena Nicoletti, Pasquale Verolino, Aimilios Lallas, Harald Kittler</p>
<p>&nbsp;</p>
<h3><strong>ABSTRACT</strong></h3>
<p><strong>Introduction</strong>: The recent WHO classification of melanocytic tumors introduces a refined molecular and histopathological framework suggesting distinct pathways and precursor lesions for all melanoma subtypes. While conceptually appealing, its clinical applicability is increasingly questioned.</p>
<p><strong>Objectives</strong>: This review critically examines the transformation theory from benign nevi to melanoma, highlighting inconsistencies between the proposed models and real-life practice.</p>
<p><strong>Methods</strong>: Through illustrative cases and key epidemiological evidence, we evaluated the validity of current models proposing intermediate lesions in melanoma development.</p>
<p><strong>Results</strong>: We argue that most melanomas arise de novo and that the so-called intermediate lesions, such as dysplastic nevi and atypical Spitz tumors, may mimic melanoma but are not true biological precursors.</p>
<p><strong>Conclusions</strong>: We propose a simplified, clinically oriented reclassification of melanocytic lesions based on morphologic ambiguity and actual behavior, aiming to guide therapeutic decisions and reduce di-agnostic overinterpretation.</p>
<p>To access the full article please <a href="https://dpcj.org/index.php/dpc/article/view/6994/3276" target="_blank" rel="noopener">click here</a>.</p>
<p>&nbsp;</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<p>The post <a href="https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/">Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</title>
		<link>https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 28 Apr 2026 04:58:45 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9638</guid>

					<description><![CDATA[<p>The post <a href="https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/">Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a3b1584ec970"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span style="color: #000000;"><span class="wi-fullname brand-fg">Maya Mundada, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Xiaochen Zhong, BA</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Alexandra So, BS; </span><a class="meta-authors--etal td-u stats-meta-authors--etal" style="color: #000000;" tabindex="0" aria-label="et al"><span aria-hidden="true">et al</span></a></span></p>
	</div>
</div>




<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<h3><strong><span style="text-decoration: underline;">Key Points</span></strong></h3>
<p>&nbsp;</p>
<p><strong>Question</strong>  What demographic, clinical, and pathological characteristics are associated with the time to recurrence of localized melanomas?</p>
<p><strong>Findings</strong>  In this cohort study of 1092 individuals diagnosed with stage IA to IIC melanomas, tumor ulceration, thickness, location on the face or scalp or neck compared with the arms, neurotropism, lymphovascular invasion, and presence of mitoses were associated with time to melanoma recurrence in multivariable analysis.</p>
<p><strong>Meaning</strong>  Results of this study suggest that factors in addition to melanoma ulceration and thickness provide an important guide for patient surveillance and counseling about potential recurrence.</p>
<p>To read more on this article please <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2845561?guestAccessKey=9161d274-2282-48bd-9ffc-a83fd3d060c7&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=etoc-tfl_&amp;utm_term=041626" target="_blank" rel="noopener">click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<p>The post <a href="https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/">Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</title>
		<link>https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 14 Apr 2026 00:44:00 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[Squamous Cell Carcinoma]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9575</guid>

					<description><![CDATA[<p>The post <a href="https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/">Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a3b1584ee794"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="name western">David Wilkinson</span>, <span class="name western">Julia Sottovia</span>, <span class="name western">Sonje Hoogstad</span></p>
<h2 data-anchor-id="abstract1">Abstract</h2>
<section id="sec1">
<h3 class="pmc_sec_title"><strong>Introduction</strong></h3>
<p>Well-differentiated squamous cell skin cancer (WDSCC) is common in sun-exposed populations. Guidelines promote active treatment, with excision preferred. Isolated cases of spontaneous regression (SR) have been reported. Having observed multiple patients with apparent SR following partial, diagnostic biopsy, we did a retrospective cohort study to explore this further.</p>
</section>
<section id="sec2">
<h3 class="pmc_sec_title"><strong>Objectives</strong></h3>
<p>We sought to report frequency of SR of WDSCC following partial biopsy by a general practitioner (GP) in a primary care setting and referral to a public hospital general surgery service for excision, to report patient characteristics, and to estimate the time interval between biopsy and SR.</p>
</section>
<section id="sec3">
<h3 class="pmc_sec_title"><strong>Methods</strong></h3>
<p>Retrospective cohort study (22 months) of patients in Queensland, Australia, with a diagnosis of WD-SCC following a partial biopsy by a GP. SR was defined as no clinical or dermoscopy evidence of squamous cell carcinoma (SCC).</p>
</section>
<section id="sec4">
<h3 class="pmc_sec_title"><strong>Results</strong></h3>
<p>Among 153 consecutive patients with WDSCC referred for excision, 51 showed SR at consultation (33.3%, 95% CI: 25.6–41). There was no significant difference in age or sex of the SR and non-SR groups. In almost all patients with SR (N=49, 96.1%), lesions were located below the knee, compared with 90 (88.2%, <em>P</em>=0.042) without SR. Average interval between biopsy and surgical consultation was 13.6 weeks (range 2.7–24.7 weeks).</p>
</section>
<section id="sec5">
<h3 class="pmc_sec_title"><strong>Conclusions</strong></h3>
<p>WDSCC may spontaneously resolve following partial, diagnostic biopsy more often than previously reported. These preliminary observations may have implications for treatment options, especially among frail patients with comorbidities.</p>
<p>For information on the full article <a href="https://dpcj.org/index.php/dpc/article/view/5632/3252" target="_blank" rel="noopener">please click here</a>.</p>
</section>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<p>The post <a href="https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/">Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title> Why Is Workplace Safety Important? Definition &#038; Essential Safety Equipment?  </title>
		<link>https://molemaxsystems.com/why-is-workplace-safety-important-definition-essential-safety-equipment/</link>
		
		<dc:creator><![CDATA[keshab]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 05:47:53 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9204</guid>

					<description><![CDATA[<p>Workplace safety is more than just a set of&#160;rules,&#160;it’s&#160;an important part of any successful business. A safe working environment protects employees from accidents, reduces health risks, and boosts overall productivity.&#160;...</p>
<p>The post <a href="https://molemaxsystems.com/why-is-workplace-safety-important-definition-essential-safety-equipment/"> Why Is Workplace Safety Important? Definition &#038; Essential Safety Equipment?  </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Workplace safety is more than just a set of&nbsp;rules,&nbsp;it’s&nbsp;an important part of any successful business. A safe working environment protects employees from accidents, reduces health risks, and boosts overall productivity.&nbsp;</p>



<p class="wp-block-paragraph">Organisations&nbsp;that&nbsp;prioritise&nbsp;safety not only safeguard their staff but also build trust, enhance&nbsp;morale&nbsp;and&nbsp;minimise&nbsp;costly disruptions.&nbsp;</p>



<p class="wp-block-paragraph">In this blog, we will explore the importance of workplace safety, highlighting the essential safety equipment every workplace should have.&nbsp;&nbsp;</p>



<h2 class="wp-block-heading"><strong>5 Effective Ways to Improve Workplace Health And Safety </strong> </h2>



<p class="wp-block-paragraph">Workplace safety is the foundation of a healthy,&nbsp;productive&nbsp;and thriving work environment. When you&nbsp;prioritise&nbsp;safety, it helps to protect employees from injuries, reduces operational disruptions, and creates a culture of trust and responsibility.&nbsp;</p>



<p class="wp-block-paragraph">Here are 5 ways to improve workplace health and safety:&nbsp;</p>



<h3 class="wp-block-heading">1. Protects Employees from Injuries and Accidents&nbsp;</h3>



<p class="wp-block-paragraph">A safe workplace helps prevent everything from minor slips and falls to severe machinery‑related accidents. In Australia, about&nbsp;<a href="https://www.safeworkaustralia.gov.au/media-centre/news/key-work-health-and-safety-statistics-2024" target="_blank" rel="noreferrer noopener">3.5 % of workers experienced a work-related injury or illness</a>&nbsp;in the past 12 months. When employers invest in safety protocols, regular&nbsp;training&nbsp;and proper protective gear, there is a high chance of reducing these risks.&nbsp;&nbsp;</p>



<h3 class="wp-block-heading">2. Boosts Productivity and Efficiency&nbsp;</h3>



<p class="wp-block-paragraph">Safety and productivity go hand in hand. Employees who feel safe at work are more focused,&nbsp;engaged&nbsp;and motivated. When you have safety equipment, there will be fewer chances of accidents, which means less downtime, smoother&nbsp;workflows&nbsp;and uninterrupted operations.&nbsp;</p>



<h3 class="wp-block-heading">3. Reduces Financial Losses&nbsp;</h3>



<p class="wp-block-paragraph">Workplace accidents can be costly in many ways. Beyond the physical harm to employees, incidents result in medical bills, workers’ compensation claims, legal fees, and higher insurance premiums. Every organisation should invest in high-quality safety tools, such as head protection and clear safety signage, along with proper training and preventive measures. </p>



<h3 class="wp-block-heading">4. Ensures Compliance with Legal Standards&nbsp;</h3>



<p class="wp-block-paragraph">Governments and regulatory bodies in Australia require businesses to meet strict work health and safety (WHS) obligations under the model WHS laws. Failure to comply can lead to hefty fines, legal complications, and damage to a company’s reputation. When you follow safety regulations, businesses not only safeguard their employees but also&nbsp;demonstrate&nbsp;professionalism and a strong commitment to ethical practices.&nbsp;&nbsp;</p>



<h3 class="wp-block-heading">5. Builds a Positive Work Culture&nbsp;</h3>



<p class="wp-block-paragraph">When staff feel valued and secure, they are more engaged, motivated, and committed to their work. It’s important to prioritise safety, encourage teamwork, accountability, and shared responsibility, and create a collaborative environment. Over time, this positive work culture not only boosts employee morale but also strengthens overall business performance. </p>



<h2 class="wp-block-heading">Essential Workplace Safety Equipment You Must Have </h2>



<p class="wp-block-paragraph">A safe work environment starts with having the right safety equipment. Proper safety gear not only protects employees from accidents and injuries but also ensures compliance with legal standards and boosts overall productivity. Whether in an office, factory, or construction site, equipping your workplace with essential safety tools is a critical step toward reducing risks and fostering a culture of care.&nbsp;</p>



<p class="wp-block-paragraph">Here are the must-have workplace safety equipment items: </p>



<h3 class="wp-block-heading"><strong>1. Personal Protective Equipment (PPE): </strong></h3>



<p class="wp-block-paragraph">Personal Protective Equipment (PPE) includes helmets, gloves, safety goggles, high-visibility clothing and protective footwear. These items shield employees from hazards such as falling objects, chemical exposure and slips, helping prevent injuries on the job. </p>



<h3 class="wp-block-heading"><strong>2. Fire Safety Equipment:</strong> </h3>



<p class="wp-block-paragraph">Fire extinguishers, smoke alarms, fire blankets and emergency exit signage are crucial for preventing and managing fire emergencies. Regularly maintaining fire safety equipment ensures quick response and reduces potential damage. </p>



<h3 class="wp-block-heading"><strong>3. First Aid Kits:</strong> </h3>



<p class="wp-block-paragraph">Every workplace should have easily accessible first aid kits stocked with bandages, antiseptics and other essential medical supplies. Quick access to first aid can prevent minor injuries from becoming severe. </p>



<h3 class="wp-block-heading"><strong>4. Safety Signage and Warnings: </strong></h3>



<p class="wp-block-paragraph">Clear signs indicating hazards, emergency exits and safety procedures are essential. Visual reminders help employees stay aware of risks and follow safety protocols consistently. </p>



<h3 class="wp-block-heading"><strong>5. Ergonomic Equipment: </strong></h3>



<p class="wp-block-paragraph">Chairs, workstations and tools designed ergonomically reduce the risk of musculoskeletal injuries. Investing in ergonomic equipment promotes employee comfort and long-term health. </p>



<h3 class="wp-block-heading"><strong>6. Emergency and Evacuation Tools:</strong></h3>



<p class="wp-block-paragraph"><strong> </strong>Items such as emergency lighting, evacuation maps and alarm systems ensure that employees can safely exit the workplace during emergencies. Proper training on these tools is equally important. </p>



<h3 class="wp-block-heading"><strong>7. Protective Barriers and Guards:</strong> </h3>



<p class="wp-block-paragraph">In high-risk areas, installing safety barriers, machine guards and handrails helps prevent accidents and protects employees from moving machinery or hazardous zones. </p>



<h2 class="wp-block-heading"><strong>Final Takeaways on Workplace Safety</strong> </h2>



<p class="wp-block-paragraph">Workplace safety tools are essential for keeping everyone protected. By implementing proper safety measures in offices, ongoing construction&nbsp;sites&nbsp;and other work environments, the risk of accidents is reduced. Fewer accidents mean lower compensation claims and uninterrupted productivity.&nbsp;</p>



<p class="wp-block-paragraph">If you’re looking for essential workplace safety tools, the <a href="https://molemaxsystems.com/" target="_blank" rel="noreferrer noopener">MoleMax system</a> is a trusted choice. As a leading medical equipment supplier in Australia, we offer a wide range of products to help you maintain a safe and compliant workplace. Our <a href="https://macquariemed.com.au/first-aid-and-safety/workplace-safety" target="_blank" rel="noreferrer noopener">workplace safety tools</a> are designed to protect employees and visitors alike, enabling businesses to create environments where safety is always the top priority. </p>
<p>The post <a href="https://molemaxsystems.com/why-is-workplace-safety-important-definition-essential-safety-equipment/"> Why Is Workplace Safety Important? Definition &#038; Essential Safety Equipment?  </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>What is Mole Mapping and How Does it Work? </title>
		<link>https://molemaxsystems.com/what-is-mole-mapping-and-how-does-it-work/</link>
		
		<dc:creator><![CDATA[keshab]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 05:46:23 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9162</guid>

					<description><![CDATA[<p>Have you ever looked at a mole and wondered if it could mean something more?&#160;It’s&#160;important to pay attention to the tiny spots on your skin because that tiny dot may...</p>
<p>The post <a href="https://molemaxsystems.com/what-is-mole-mapping-and-how-does-it-work/">What is Mole Mapping and How Does it Work? </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Have you ever looked at a mole and wondered if it could mean something more?&nbsp;It’s&nbsp;important to pay attention to the tiny spots on your skin because that tiny dot may turn into cancer. Mole mapping is a medical procedure that uses high-resolution photography and digital&nbsp;dermoscopic&nbsp;imaging to create a detailed, visual record of all your moles.&nbsp;</p>



<p class="wp-block-paragraph">In this blog,&nbsp;you’ll&nbsp;learn exactly what mole mapping is, how it works, and which mole changes should be checked early to prevent severe skin cancer risks.&nbsp;</p>



<h2 class="wp-block-heading"><strong>Mole Mapping&nbsp;</strong>&nbsp;</h2>



<p class="wp-block-paragraph">Mole mapping is a medical procedure that uses high-resolution photography and digital&nbsp;dermoscopic&nbsp;imaging to create a detailed record of all the moles on your body. </p>



<p class="wp-block-paragraph">Dermatologists, general&nbsp;practitioners,&nbsp;and skin health practitioners use these images during follow-up visits to compare changes over time, helping them detect suspicious growths or early signs of skin cancer before they become serious. Not every mole turns cancerous, but keeping an eye on them is important because early detection makes treatment much easier and more effective.&nbsp;</p>



<h2 class="wp-block-heading"><strong>What Do the Moles&nbsp;On&nbsp;Your Body Mean?&nbsp;&nbsp;</strong></h2>



<p class="wp-block-paragraph">Moles are harmless skin growths formed by clusters of pigment-producing cells called melanocytes. Most moles are normal, but some can&nbsp;indicate&nbsp;a higher risk of skin cancer, especially if they change in size, shape, or&nbsp;colour. Moles can last more than 50 years.&nbsp;It’s&nbsp;important to see a healthcare provider or dermatologist if you notice any suspicious changes in your skin.&nbsp;They use advanced digital devices to examine moles closely and track their evolution.&nbsp;&nbsp;</p>



<h2 class="wp-block-heading"><strong>What Happens During Mole Mapping?&nbsp;</strong>&nbsp;</h2>



<p class="wp-block-paragraph">During mole mapping, a medical practitioner or skin health practitioner takes high-resolution photos of your entire body and closely examines each mole using a&nbsp;dermatoscope. They document and highlight any moles that look unusual or have the potential to turn into melanoma or other types of skin cancer. These images are then stored and compared over time to spot even the smallest changes early. Dermatologists and medical practitioners use advanced digital systems like&nbsp;<strong>MoleMax</strong>, which provide clear images to support precise diagnosis and early skin cancer detection.&nbsp;</p>



<h2 class="wp-block-heading"><strong>How Mole Mapping Works with Advanced Systems Like&nbsp;MoleMax?</strong>&nbsp;</h2>



<p class="wp-block-paragraph">MoleMax&nbsp;software is an effective, painless system that uses high-resolution photography and&nbsp;dermoscopic&nbsp;imaging to document,&nbsp;monitor&nbsp;and track moles. Detecting changes early helps protect you from potential skin cancer.&nbsp;</p>



<p class="wp-block-paragraph">Here’s&nbsp;the Mole Mapping Process with&nbsp;MoleMax:&nbsp;</p>



<h3 class="wp-block-heading">1. Total Body Photography (TBP)&nbsp;</h3>



<p class="wp-block-paragraph">MoleMax&nbsp;captures detailed,&nbsp;standardised&nbsp;photos of your entire body to record every mole in its exact location. This creates a baseline for future comparisons and ensures that no mole goes unnoticed.&nbsp;</p>



<h3 class="wp-block-heading">2. Close-Up&nbsp;Dermatoscopic&nbsp;Imaging&nbsp;</h3>



<p class="wp-block-paragraph"><a href="https://molemaxsystems.com/product-molemax-hd-pro/" target="_blank" rel="noreferrer noopener">Molemax HD pro</a>&nbsp;device used to get a close-up image:&nbsp;</p>



<ul class="wp-block-list">
<li>Examine structure,&nbsp;colour&nbsp;and patterns in detail (ABCDE) method.&nbsp;&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Detect subtle changes that are invisible to the naked eye.&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Track mole evolution over time for early skin cancer detection.&nbsp;</li>
</ul>



<h3 class="wp-block-heading">3. Digital Storage and Tracking&nbsp;</h3>



<p class="wp-block-paragraph">All images are securely stored in the&nbsp;MoleMax&nbsp;System. During follow-ups, your medical professional can compare new images with&nbsp;previous&nbsp;ones, detecting even subtle changes over time.&nbsp;</p>



<h3 class="wp-block-heading">4. Early Detection Alerts&nbsp;</h3>



<p class="wp-block-paragraph">The&nbsp;MoleMax&nbsp;System highlights moles that show irregularities or changes, which allows the medical professional to&nbsp;prioritise&nbsp;examination and intervene early if necessary, reducing the risk of skin cancer.&nbsp;</p>



<h3 class="wp-block-heading">5. Patient Awareness and Education&nbsp;</h3>



<p class="wp-block-paragraph">Patients can view their mole maps, understand their skin&nbsp;health&nbsp;and learn which moles to&nbsp;monitor, encouraging regular self-checks between appointments.&nbsp;</p>
<p>The post <a href="https://molemaxsystems.com/what-is-mole-mapping-and-how-does-it-work/">What is Mole Mapping and How Does it Work? </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dermoscopy vs Digital Dermoscopy: What’s the Difference? </title>
		<link>https://molemaxsystems.com/dermoscopy-vs-digital-dermoscopy-whats-the-difference/</link>
		
		<dc:creator><![CDATA[keshab]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 05:39:11 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9435</guid>

					<description><![CDATA[<p>Dermoscopy&#160;and digital&#160;dermoscopy&#160;are closely related but fundamentally different tools in modern skin examination. Both are used to&#160;visualise&#160;subsurface skin structures not visible to the naked eye, yet they differ significantly in how...</p>
<p>The post <a href="https://molemaxsystems.com/dermoscopy-vs-digital-dermoscopy-whats-the-difference/">Dermoscopy vs Digital Dermoscopy: What’s the Difference? </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Dermoscopy&nbsp;and digital&nbsp;dermoscopy&nbsp;are closely related but fundamentally different tools in modern skin examination. Both are used to&nbsp;visualise&nbsp;subsurface skin structures not visible to the naked eye, yet they differ significantly in how images are captured, stored,&nbsp;reviewed&nbsp;and used over time.&nbsp;</p>



<p class="wp-block-paragraph">Understanding these differences is essential for clinics focused on&nbsp;accurate&nbsp;documentation, follow-up&nbsp;and consistent clinical workflow rather than single-visit assessment alone.&nbsp;</p>



<h2 class="wp-block-heading">What Is&nbsp;Dermoscopy?&nbsp;</h2>



<p class="wp-block-paragraph">Dermoscopy&nbsp;is an optical examination technique using a handheld&nbsp;dermatoscope&nbsp;that provides magnification and&nbsp;specialised&nbsp;lighting. It allows clinicians to assess patterns,&nbsp;colours, and structures within a&nbsp;<a href="https://molemaxsystems.com/managing-a-pigmented-skin-lesion-on-the-foot/" target="_blank" rel="noreferrer noopener"><strong>pigmented skin lesion</strong></a>&nbsp;during a live consultation.&nbsp;</p>



<p class="wp-block-paragraph">The assessment is immediate and relies heavily on clinician experience and visual interpretation. Findings are typically recorded as written notes, diagrams, or memory-based descriptions.&nbsp;</p>



<h2 class="wp-block-heading">When Traditional&nbsp;Dermoscopy&nbsp;Is Sufficient&nbsp;</h2>



<ul class="wp-block-list">
<li>One-off lesion assessments&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Low-risk patients with limited follow-up needs&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Situations where image storage is not&nbsp;required&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Clinics relying primarily on clinician recall&nbsp;</li>
</ul>



<p class="wp-block-paragraph">Dermoscopy&nbsp;remains&nbsp;essential for&nbsp;recognising&nbsp;structures associated with&nbsp;<a href="https://molemaxsystems.com/one-clue-two-outcomes-benign-vs-malignant-through-dermoscopy/" target="_blank" rel="noreferrer noopener"><strong>Malignant Through&nbsp;Dermoscopy</strong></a>, particularly when rapid decision-making is&nbsp;required.&nbsp;</p>



<h2 class="wp-block-heading">What Is Digital&nbsp;Dermoscopy?&nbsp;</h2>



<p class="wp-block-paragraph">Digital&nbsp;dermoscopy&nbsp;builds on&nbsp;traditional&nbsp;dermoscopy&nbsp;by adding image capture,&nbsp;storage&nbsp;and retrieval. Instead of relying only on live optical viewing, images are saved and linked directly to the&nbsp;patient&nbsp;record.&nbsp;</p>



<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="350" src="https://molemaxsystems.com/wp-content/uploads/2026/01/MoleMax-Systems-Website-Banners-1900-x-650-px-1-1024x350.gif" alt="digital dermoscopy" class="wp-image-9035" srcset="https://molemaxsystems.com/wp-content/uploads/2026/01/MoleMax-Systems-Website-Banners-1900-x-650-px-1-1024x350.gif 1024w, https://molemaxsystems.com/wp-content/uploads/2026/01/MoleMax-Systems-Website-Banners-1900-x-650-px-1-300x103.gif 300w, https://molemaxsystems.com/wp-content/uploads/2026/01/MoleMax-Systems-Website-Banners-1900-x-650-px-1-768x263.gif 768w, https://molemaxsystems.com/wp-content/uploads/2026/01/MoleMax-Systems-Website-Banners-1900-x-650-px-1-1536x525.gif 1536w, https://molemaxsystems.com/wp-content/uploads/2026/01/MoleMax-Systems-Website-Banners-1900-x-650-px-1-600x205.gif 600w, https://molemaxsystems.com/wp-content/uploads/2026/01/MoleMax-Systems-Website-Banners-1900-x-650-px-1-400x137.gif 400w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



<p class="wp-block-paragraph">This allows clinicians to:&nbsp;</p>



<ul class="wp-block-list">
<li>Compare lesions across time&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Review images before or after appointments&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Share visual findings during patient discussions&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Support structured documentation and reporting&nbsp;</li>
</ul>



<p class="wp-block-paragraph">Digital&nbsp;dermoscopy&nbsp;shifts skin checks from memory-based assessment to evidence-based longitudinal monitoring.&nbsp;</p>



<h2 class="wp-block-heading">Dermoscopy&nbsp;vs Digital&nbsp;Dermoscopy: Core Differences&nbsp;</h2>



<h3 class="wp-block-heading">Image Capture and Storage&nbsp;</h3>



<ul class="wp-block-list">
<li><strong>Dermoscopy:</strong>&nbsp;Live optical view only&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li><strong>Digital&nbsp;dermoscopy:</strong>&nbsp;High-quality images saved with patient records&nbsp;</li>
</ul>



<h3 class="wp-block-heading">Documentation&nbsp;</h3>



<ul class="wp-block-list">
<li><strong>Dermoscopy:</strong>&nbsp;Written notes and diagrams&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li><strong>Digital&nbsp;dermoscopy:</strong>&nbsp;Image-linked documentation, measurements, and annotations&nbsp;</li>
</ul>



<h3 class="wp-block-heading">Follow-Up&nbsp;</h3>



<ul class="wp-block-list">
<li><strong>Dermoscopy:</strong>&nbsp;Relies on recall and written descriptions&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li><strong>Digital&nbsp;dermoscopy:</strong>&nbsp;Enables side-by-side image comparison over time&nbsp;</li>
</ul>



<h3 class="wp-block-heading">Workflow Consistency&nbsp;</h3>



<ul class="wp-block-list">
<li><strong>Dermoscopy:</strong>&nbsp;Varies between clinicians&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li><strong>Digital&nbsp;dermoscopy:</strong>&nbsp;Standardised&nbsp;capture and reporting protocols&nbsp;</li>
</ul>



<h2 class="wp-block-heading">Clinical Workflow Differences That Matter&nbsp;</h2>



<p class="wp-block-paragraph">In daily practice, the difference is not diagnostic intent but operational reliability. Digital&nbsp;dermoscopy&nbsp;reduces rework caused by missing images, unclear lesion&nbsp;localisation, or incomplete notes. This is particularly relevant when&nbsp;monitoring&nbsp;lesions such as&nbsp;<strong>Dysplastic Naevus&nbsp;dermoscopy</strong>, where subtle changes over time are clinically meaningful but difficult to recall accurately without images.&nbsp;</p>



<h2 class="wp-block-heading">Follow-Up and Monitoring Over Time&nbsp;</h2>



<p class="wp-block-paragraph">The true value of digital&nbsp;dermoscopy&nbsp;appears during follow-up. Sequential imaging allows clinicians to confirm stability or detect change without relying on memory. This is critical for patients with multiple lesions or increased skin cancer risk.&nbsp;</p>



<p class="wp-block-paragraph">Digital systems support:&nbsp;</p>



<ul class="wp-block-list">
<li>Sequential lesion review&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Reduced unnecessary excisions&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Better confidence in “watch and wait” decisions&nbsp;</li>
</ul>



<p class="wp-block-paragraph">Follow-up protocols are also commonly discussed alongside preventative strategies, including patient education topics such as&nbsp;<a href="https://molemaxsystems.com/nicotinamide-for-skin-cancer-chemoprevention/" target="_blank" rel="noreferrer noopener"><strong>Nicotinamide for skin cancer</strong></a>, where ongoing monitoring&nbsp;remains&nbsp;essential even with risk-reduction measures.&nbsp;</p>



<h2 class="wp-block-heading">Patient Communication and Understanding&nbsp;</h2>



<p class="wp-block-paragraph">Digital&nbsp;dermoscopy&nbsp;improves transparency. Patients can see exactly what the clinician is reviewing, making explanations&nbsp;clearer&nbsp;and improving confidence in management plans. </p>



<p class="wp-block-paragraph">Visual review is particularly helpful when explaining why a lesion is benign,&nbsp;changing&nbsp;or requires monitoring.&nbsp;</p>



<p class="wp-block-paragraph">This is especially useful when discussing complex or atypical&nbsp;<strong>pigmented skin lesion</strong>&nbsp;patterns that are difficult to describe verbally.&nbsp;</p>



<h2 class="wp-block-heading">Common Misconceptions About Digital&nbsp;Dermoscopy&nbsp;</h2>



<ul class="wp-block-list">
<li>It does not replace clinical judgement&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>It does not diagnose cancer on its own&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>It is not limited to specialist clinics&nbsp;</li>
</ul>



<p class="wp-block-paragraph">Digital&nbsp;<a href="https://molemaxsystems.com/product-category/dermlite/dermatoscopes/" target="_blank" rel="noreferrer noopener">dermoscopy</a>&nbsp;is a documentation and follow-up tool. Its value lies in consistency,&nbsp;traceability&nbsp;and workflow support rather than standalone diagnostic claims.&nbsp;</p>



<h2 class="wp-block-heading">How Clinics Decide When to Move Beyond Handheld&nbsp;Dermoscopy&nbsp;</h2>



<p class="wp-block-paragraph">Clinics typically consider digital&nbsp;dermoscopy&nbsp;when:&nbsp;</p>



<ul class="wp-block-list">
<li>Patient volume increases&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Follow-up intervals become routine&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Multiple clinicians need consistent records&nbsp;</li>
</ul>



<ul class="wp-block-list">
<li>Image-based referrals are&nbsp;required&nbsp;</li>
</ul>



<p class="wp-block-paragraph">The transition is usually driven by workflow needs rather than technology preference.&nbsp;</p>



<h2 class="wp-block-heading">Summary:&nbsp;Dermoscopy&nbsp;vs Digital&nbsp;Dermoscopy&nbsp;</h2>



<p class="wp-block-paragraph">Dermoscopy&nbsp;provides immediate visual assessment.&nbsp;Digital&nbsp;dermoscopy&nbsp;adds documentation,&nbsp;comparison&nbsp;and continuity.&nbsp;</p>



<p class="wp-block-paragraph">Both tools are clinically valuable, but they serve&nbsp;different roles.&nbsp;Dermoscopy&nbsp;supports moment-in-time evaluation, while digital&nbsp;dermoscopy&nbsp;supports longitudinal care, structured follow-up&nbsp;and consistent communication.&nbsp;</p>



<h2 class="wp-block-heading"><strong>Frequently Asked Questions (FAQs)</strong>&nbsp;</h2>



<h3 class="wp-block-heading"><strong>Is digital&nbsp;dermoscopy&nbsp;more&nbsp;accurate&nbsp;than&nbsp;dermoscopy?</strong>&nbsp;</h3>



<p class="wp-block-paragraph">Digital&nbsp;dermoscopy&nbsp;does not change the optical principles of&nbsp;dermoscopy. Its advantage lies in documentation and comparison, not inherent diagnostic accuracy.&nbsp;</p>



<h3 class="wp-block-heading"><strong>Do all clinics need digital&nbsp;dermoscopy?</strong>&nbsp;</h3>



<p class="wp-block-paragraph">No. Clinics with low follow-up volume or&nbsp;predominantly one-off&nbsp;assessments may rely effectively on handheld&nbsp;dermoscopy&nbsp;alone.&nbsp;</p>



<h3 class="wp-block-heading"><strong>Can digital&nbsp;dermoscopy&nbsp;replace biopsies?</strong>&nbsp;</h3>



<p class="wp-block-paragraph">No. Digital&nbsp;dermoscopy&nbsp;supports monitoring and decision-making but does not replace histopathological confirmation when clinically&nbsp;indicated.&nbsp;</p>
<p>The post <a href="https://molemaxsystems.com/dermoscopy-vs-digital-dermoscopy-whats-the-difference/">Dermoscopy vs Digital Dermoscopy: What’s the Difference? </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
